Technology Allows Faster Creation of Knock-In Cell Lines with Multiple Genes Inserted
PHILADELPHIA – Jan. 19, 2021 – PRLog — ExpressCells, Inc. (“ExpressCells”), a genetic engineering company that creates knock-in cell lines for biological research, announces the granting of the first patent for its core FAST-HDR gene editing technology. The United States Patent & Trademark Office (USPTO) issued the patent on January 5, 2021.
US Patent Number 10,883,120 covers the FAST-HDR empty vector that it is used to rapidly create donor templates for inserting DNA into the genome of mammalian cells. The donor templates are used in combination with CRISPR endonucleases to insert new genetic information into living cells by promoting a natural process called homology donor repair (HDR). This is the process that allows for faster, precise insertion of genes that tailor cells to the scientist’s experiment. The inventor on the patent is ExpressCells’ co-founder, Oscar Perez Leal, MD, a Scientific Advisor to ExpressCells and an Assistant Professor at Temple University School of Pharmacy. The patent is assigned to Temple University, which has granted a global, exclusive license to ExpressCells.
Better Knock-ins, Better Cell Lines, Better Science
ExpressCells leverages proprietary gene-editing tools to customize human cell lines for drug discovery, toxicology, and other biologic research.
"*" indicates required fields